在转移性软组织肉瘤中,pazopanib治疗的响应率使用真实世界的数据
Cem Murat Söylemez1, Pinar Gürsoy2, Ulus Ali Şanli2
1Department of Medical Oncology, University of Health Science Izmir Tepecik Research and Training Hospital, Bornova, Izmir 35110, Turkey.
Oncology letters
|December 31, 2024
概括
帕佐帕尼布在转移性软组织肉瘤患者中显示了46.3%的临床响应率. 帕佐帕尼布治疗的有利因素包括特定的亚型,低瘤等级和更少的转移部位.
科学领域:
- 医学瘤学 医学瘤学
- 临床药理学 临床药理学
背景情况:
- 转移性软组织肉瘤 (STS) 的治疗选择有限.
- 帕佐帕尼布是一种多向的氨酸激酶抑制剂,用于STS治疗.
研究的目的:
- 评估pazopanib在一组多样化的转移性STS患者中的疗效和安全性.
- 确定与STS中pazopanib反应相关的临床因素.
主要方法:
- 对81名转移性STS患者进行了回顾性单中心研究,这些患者接受了pazopanib.
- 收集的数据包括患者人口统计学,组织学亚型,先前治疗,转移部位,生存结果,副作用和成像反应.
- 对无进展生存 (PFS),总生存 (OS) 和临床反应率 (RR) 的分析.
主要成果:
- 中位数的生存期为46个月,中位数的PFS为5个月,整体临床反应率为46.3%.
- 血管内皮瘤和膜软部肉瘤显示出改善的反应.
- 低瘤等级和更少的转移部位与改善的反应有关,尽管并不总是统计学上显著.
- 帕佐帕尼布在一般情况下被很好地容忍.
结论:
- 帕佐帕尼布在转移性STS中表现出显著的响应率和良好的耐受性.
- 特定的亚型,较低的瘤等级和较少的转移部位可能预测更好的结果.
- 帕佐帕尼布是选择性转移性STS患者的可行的治疗选择,特别是在早期的治疗线上.
相关概念视频
02:56Treatment Resistant Cancers
Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
02:56Treatment Resistent Cancers
Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...